• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

罕见和超罕见遗传性共济失调评估和分级评定量表的项目表现。

Item performance of the scale for the assessment and rating of ataxia in rare and ultra-rare genetic ataxias.

机构信息

Pharmacometrics Research Group, Department of Pharmacy, Uppsala University, Uppsala, Sweden.

Department of Neurodegenerative Diseases, Center for Neurology and Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.

出版信息

CPT Pharmacometrics Syst Pharmacol. 2024 Aug;13(8):1327-1340. doi: 10.1002/psp4.13162. Epub 2024 May 21.

DOI:10.1002/psp4.13162
PMID:38769902
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11330187/
Abstract

The Scale for the Assessment and Rating of Ataxia (SARA) is widely used for assessing the severity and progression of genetic cerebellar ataxias. SARA is now considered a primary end point in several ataxia treatment trials, but its underlying composite item measurement model has not yet been tested. This work aimed to evaluate the composite properties of SARA and its items using item response theory (IRT) and to demonstrate its applicability across even ultra-rare genetic ataxias. Leveraging SARA subscores data from 1932 visits from 990 patients of the Autosomal Recessive Cerebellar Ataxias (ARCA) registry, we assessed the performance of SARA using IRT methodology. The item characteristics were evaluated over the ataxia severity range of the entire ataxia population as well as the assessment validity across 115 genetic ARCA subpopulations. A unidimensional IRT model was able to describe SARA item data, indicating that SARA captures one single latent variable. All items had high discrimination values (1.5-2.9) indicating the effectiveness of the SARA in differentiating between subjects with different disease statuses. Each item contributed between 7% and 28% of the total assessment informativeness. There was no evidence for differences between the 115 genetic ARCA subpopulations in SARA applicability. These results show the good discrimination ability of SARA with all of its items adding informational value. The IRT framework provides a thorough description of SARA on the item level, and facilitates its utilization as a clinical outcome assessment in upcoming longitudinal natural history or treatment trials, across a large number of ataxias, including ultra-rare ones.

摘要

用于评估遗传性小脑共济失调严重程度和进展的量表(SARA)得到广泛应用。SARA 现在被认为是几种共济失调治疗试验的主要终点,但它的基本综合项目测量模型尚未得到测试。本研究旨在使用项目反应理论(IRT)评估 SARA 及其项目的综合特性,并证明其在包括超罕见遗传性共济失调在内的多种共济失调中的适用性。利用 Autosomal Recessive Cerebellar Ataxias(ARCA)登记处的 990 名患者的 1932 次就诊的 SARA 子评分数据,我们使用 IRT 方法评估了 SARA 的性能。在整个共济失调人群的共济失调严重程度范围内以及在 115 个遗传 ARCA 亚群中的评估有效性,评估了项目特征。单维 IRT 模型能够描述 SARA 项目数据,表明 SARA 捕获了一个单一的潜在变量。所有项目的辨别力值都很高(1.5-2.9),表明 SARA 能够有效地区分不同疾病状态的受试者。每个项目对总评估信息量的贡献在 7%至 28%之间。在 SARA 的适用性方面,115 个遗传 ARCA 亚群之间没有差异的证据。这些结果表明 SARA 及其所有项目都具有良好的辨别能力,并且都增加了信息量。IRT 框架在项目级别上提供了对 SARA 的全面描述,并促进了其在未来的纵向自然史或治疗试验中作为临床结局评估的使用,涵盖了大量的共济失调,包括超罕见的共济失调。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5759/11330187/6a70b4332b7f/PSP4-13-1327-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5759/11330187/03bd12eaac10/PSP4-13-1327-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5759/11330187/bdf9bc9032ba/PSP4-13-1327-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5759/11330187/4fb044b23ac6/PSP4-13-1327-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5759/11330187/970399ea9ae3/PSP4-13-1327-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5759/11330187/6a70b4332b7f/PSP4-13-1327-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5759/11330187/03bd12eaac10/PSP4-13-1327-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5759/11330187/bdf9bc9032ba/PSP4-13-1327-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5759/11330187/4fb044b23ac6/PSP4-13-1327-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5759/11330187/970399ea9ae3/PSP4-13-1327-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5759/11330187/6a70b4332b7f/PSP4-13-1327-g004.jpg

相似文献

1
Item performance of the scale for the assessment and rating of ataxia in rare and ultra-rare genetic ataxias.罕见和超罕见遗传性共济失调评估和分级评定量表的项目表现。
CPT Pharmacometrics Syst Pharmacol. 2024 Aug;13(8):1327-1340. doi: 10.1002/psp4.13162. Epub 2024 May 21.
2
Longitudinal Analysis of Natural History Progression of Rare and Ultra-Rare Cerebellar Ataxias Using Item Response Theory.基于项目反应理论的罕见和极罕见小脑共济失调自然史进展的纵向分析。
Clin Pharmacol Ther. 2024 Dec;116(6):1593-1605. doi: 10.1002/cpt.3466. Epub 2024 Oct 15.
3
Prediction of Individual Disease Progression Including Parameter Uncertainty in Rare Neurodegenerative Diseases: The Example of Autosomal-Recessive Spastic Ataxia Charlevoix Saguenay (ARSACS).罕见神经退行性疾病中包含参数不确定性的个体疾病进展预测:常染色体隐性痉挛性共济失调 Charlevoix Saguenay (ARSACS) 的实例。
AAPS J. 2024 Apr 30;26(3):57. doi: 10.1208/s12248-024-00925-7.
4
FARS-ADL across Ataxias: Construct Validity, Sensitivity to Change, and Minimal Important Change.FARS-ADL 在各种共济失调中的表现:构念效度、变化敏感性和最小有意义变化。
Mov Disord. 2024 Jun;39(6):965-974. doi: 10.1002/mds.29788. Epub 2024 Mar 20.
5
SARA captures disparate progression and responsiveness in spinocerebellar ataxias.SARA 捕获了脊髓小脑共济失调中的不同进展和反应。
J Neurol. 2024 Jul;271(7):3743-3753. doi: 10.1007/s00415-024-12475-1. Epub 2024 Jun 1.
6
Responsiveness of the Scale for the Assessment and Rating of Ataxia and Natural History in 884 Recessive and Early Onset Ataxia Patients.《884 例隐性和早发性共济失调患者的共济失调评估和评定量表的反应性及自然病史》。
Ann Neurol. 2023 Sep;94(3):470-485. doi: 10.1002/ana.26712. Epub 2023 Jun 12.
7
Scale for the assessment and rating of ataxia: Age-dependent performance of healthy adults.共济失调评估与评分量表:健康成年人的年龄相关表现
Eur J Neurol. 2023 Feb;30(2):548-551. doi: 10.1111/ene.15596. Epub 2022 Oct 26.
8
Friedreich and dominant ataxias: quantitative differences in cerebellar dysfunction measurements.弗里德里希共济失调和显性共济失调:小脑功能测量的定量差异。
J Neurol Neurosurg Psychiatry. 2018 Jun;89(6):559-565. doi: 10.1136/jnnp-2017-316964. Epub 2017 Dec 26.
9
Assessment of Ataxia Rating Scales and Cerebellar Functional Tests: Critique and Recommendations.共济失调评定量表与小脑功能测试的评估:批判与建议
Mov Disord. 2021 Feb;36(2):283-297. doi: 10.1002/mds.28313. Epub 2020 Oct 6.
10
Temporal Dynamics of the Scale for the Assessment and Rating of Ataxia in Spinocerebellar Ataxias.脊髓小脑共济失调评定量表的时间动态评估。
Mov Disord. 2023 Jan;38(1):35-44. doi: 10.1002/mds.29255. Epub 2022 Oct 23.

引用本文的文献

1
Comparing randomized trial designs to estimate treatment effect in rare diseases with longitudinal models: a simulation study showcased by Autosomal Recessive Cerebellar Ataxias using the SARA score.使用纵向模型比较随机试验设计以估计罕见疾病的治疗效果:一项以常染色体隐性遗传性小脑共济失调为例、采用SARA评分的模拟研究
BMC Med Res Methodol. 2025 Jul 30;25(1):179. doi: 10.1186/s12874-025-02626-x.
2
Assessment of the reliability, responsiveness, and meaningfulness of the scale for the assessment and rating of ataxia (SARA) for lysosomal storage disorders.评估用于溶酶体贮积症的共济失调评估与分级量表(SARA)的可靠性、反应性和意义。
J Neurol. 2024 Oct;271(10):6888-6902. doi: 10.1007/s00415-024-12664-y. Epub 2024 Sep 3.

本文引用的文献

1
N-acetyl-L-leucine for Niemann-Pick type C: a multinational double-blind randomized placebo-controlled crossover study.N-乙酰-L-亮氨酸治疗尼曼-匹克 C 型:一项多中心、双盲、随机、安慰剂对照交叉研究。
Trials. 2023 May 29;24(1):361. doi: 10.1186/s13063-023-07399-6.
2
Responsiveness of the Scale for the Assessment and Rating of Ataxia and Natural History in 884 Recessive and Early Onset Ataxia Patients.《884 例隐性和早发性共济失调患者的共济失调评估和评定量表的反应性及自然病史》。
Ann Neurol. 2023 Sep;94(3):470-485. doi: 10.1002/ana.26712. Epub 2023 Jun 12.
3
Autosomal Recessive Cerebellar Ataxias in Europe: Frequency, Onset, and Severity in 677 Patients.
欧洲常染色体隐性遗传性小脑共济失调:677例患者的发病率、发病年龄及严重程度
Mov Disord. 2023 Jun;38(6):1109-1112. doi: 10.1002/mds.29397. Epub 2023 Apr 7.
4
Digital Gait Biomarkers Allow to Capture 1-Year Longitudinal Change in Spinocerebellar Ataxia Type 3.数字步态生物标志物可捕捉到脊髓小脑共济失调 3 型长达 1 年的纵向变化。
Mov Disord. 2022 Nov;37(11):2295-2301. doi: 10.1002/mds.29206. Epub 2022 Aug 31.
5
Differential Temporal Dynamics of Axial and Appendicular Ataxia in SCA3.SCA3 中轴性和肢体性共济失调的差异时间动态。
Mov Disord. 2022 Sep;37(9):1850-1860. doi: 10.1002/mds.29135. Epub 2022 Jul 8.
6
Autosomal Recessive Cerebellar Ataxias in South America: A Multicenter Study of 1338 Patients.南美洲常染色体隐性遗传性小脑共济失调:1338例患者的多中心研究
Mov Disord. 2022 Aug;37(8):1773-1774. doi: 10.1002/mds.29046. Epub 2022 May 4.
7
Paving the Way Toward Meaningful Trials in Ataxias: An Ataxia Global Initiative Perspective.为共济失调领域开展有意义的试验铺平道路:共济失调全球倡议视角
Mov Disord. 2022 Jun;37(6):1125-1130. doi: 10.1002/mds.29032. Epub 2022 Apr 27.
8
Safety and efficacy of riluzole in spinocerebellar ataxia type 2 in France (ATRIL): a multicentre, randomised, double-blind, placebo-controlled trial.在法国(ATRIL)进行的利鲁唑治疗脊髓小脑共济失调 2 型的安全性和疗效:一项多中心、随机、双盲、安慰剂对照试验。
Lancet Neurol. 2022 Mar;21(3):225-233. doi: 10.1016/S1474-4422(21)00457-9. Epub 2022 Jan 18.
9
Safety and Efficacy of Acetyl-DL-Leucine in Certain Types of Cerebellar Ataxia: The ALCAT Randomized Clinical Crossover Trial.乙酰-DL-亮氨酸治疗某些类型小脑共济失调的安全性和疗效:ALCAT 随机临床交叉试验。
JAMA Netw Open. 2021 Dec 1;4(12):e2135841. doi: 10.1001/jamanetworkopen.2021.35841.
10
Preparing n-of-1 Antisense Oligonucleotide Treatments for Rare Neurological Diseases in Europe: Genetic, Regulatory, and Ethical Perspectives.为欧洲罕见神经疾病制备反义寡核苷酸治疗药物:遗传、监管和伦理视角。
Nucleic Acid Ther. 2022 Apr;32(2):83-94. doi: 10.1089/nat.2021.0039. Epub 2021 Sep 29.